Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Clinical Pharmacology
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Clinical Pharmacology
    Vitespen Shows No Increased Survival in Postoperative Renal Cell Carcinoma Patients - (DGNews)
    European Commission Approves Methylnaltrexone Bromide for Opioid-Induced Constipation in Advanced Illness - (DGNews)
    HAART May Increase Asthma Risk in Children With HIV - (DGNews)
    Multitarget Immune Therapy Improves Outcomes of Severe Lupus Nephritis - (DGNews)
    Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty - (N Engl J Med)

    News archive

     Recent webcasts/CME - Clinical Pharmacology
      Enhanced NSAID Delivery: Emerging Technologies
      The Use of Saline Nasal Irrigation in Common Upper Respiratory Conditions
      Balanced Opioid Prescribing
      Persistent, Not Permanent: Alleviating Symptoms in Chronic Knee Pain
      Update on the Management of Acute Decompensated Heart Failure: Incorporating Treatment Guidelines and Recent Clinical Research Findings into Practice

      Webcasts/CME archive

       Recent cases - Clinical Pharmacology
        Decrease in Tobacco Consumption After Treatment with Topiramate and Aripiprazole
        Topiramate-Induced Psychosis in Two Members of the One Family: A Case Report
        Successful Treatment of Kasabach-Merritt Syndrome with Vincristine and Surgery: A Case Report and Review of Literature
        Tender Nodules on the Palms and Soles After Chemotherapy
        Glucocorticoid Hypersensitivity as a Rare but Potentially Fatal Side Effect of Paediatric Asthma Treatment: A Case Report

        Cases archive
          




        my personal edition > clinical pharmacology > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Donepezil Benefits Alzheimer's Patients With Comorbidities

        A DGReview of :"Efficacy and safety of donepezil in patients with Alzheimer's disease : results of a global, multinational, clinical experience study"
        Drugs & Aging

        02/05/2004
        By Emma Hitt, PhD


        Donepezil appears to be effective and well tolerated in the treatment of mild-to-moderate Alzheimer's disease, according to the findings of an open-label multicentre trial.

        In previous trial, donepezil was found to be effective and well tolerated, and it has been shown to provide significant benefits in cognition, global function and activities of daily living in patients with mild-to-moderate Alzheimer's disease. However, its efficacy in patients with comorbid illness and/or concomitant medication use is less clear.

        Merce Boada-Rovira, MD, with Fundacio ACE, Barcelona, Spain, and colleagues conducted a 12-week trial of 1,113 patients with probable mild-to-moderate Alzheimer's disease enrolled at 246 study centres in 18 countries worldwide. About three fourths of the patients were taking at least one concomitant medication and two thirds had at least one comorbid medical condition on study entry. The patients' mean baseline MMSE score was 18.74.

        Patients received donepezil 5 mg/day for 28 days, after which the dosage was increased to 10 mg/day depending upon the clinician's judgment. A trained clinician assessed cognition with the Mini-Mental State Examination (MMSE) at baseline, week 4 and week 12 (or last visit).

        Changes in patient activity and social interaction were evaluated with a caregiver diary, in which caregivers recorded their impression of change in patient behaviour using a 5-point scale.

        A total of 88.9% of patients completed the study and 5% of patients discontinued because of adverse events. Donepezil significantly improved cognition compared with baseline at weeks 4 and 12 (P < .0001). Mean change from baseline MMSE score was 1.73.

        According to the researchers, donepezil was also associated with significant improvements in patient social interaction, engagement and interest, and initiation of pleasurable activities (all P < .0001). In addition, donepezil was generally well tolerated.

        "The results of this open-label study received placebo in a previous 12-week, double- conducted in a large population of unselected patients are consistent with those of controlled trials and extend the knowledge of the risk benefit ratio of donepezil when used in a 'real-world' setting," Dr. Boada-Rovira and colleagues conclude.

        Drugs Aging 2004;21:1:43-53. "Efficacy and safety of donepezil in patients with Alzheimer's disease : results of a global, multinational, clinical experience study"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send